ROHDE-&-SCHWARZ
21.10.2020 15:02:11 CEST | Business Wire | Press release
In the past, the creation of software took about a year on average of development before being commercialized. Today, many organizations are adopting a continuous integration and deployment approach. Now, the cycle has become shorter, thanks in particular to DevOps, which relies on automation and the pooling of complementary skills to increase the added-value and responsiveness of companies.
The Rohde & Schwarz Cybersecurity strategy aims to help DevOps teams integrate application security right from the design phase, by integrating control capabilities within their APIs and applications. Rohde & Schwarz Cybersecurity has been offering Web Application Firewall (WAF) technologies for about twenty years. The company now makes its technologies consumable by developers. It offers tools that integrate into the environment and tools already existing and that use the same languages and technologies of the DevSecOps universe. It is in this context that Rohde & Schwarz Cybersecurity is launching R&S Trusted Application Factory.
Putting security at the heart of applications
R&S Trusted Application Factory is a solution for DevOps teams with the objective of providing security, simplicity and visibility.
- Security : By integrating security as close as possible to the application
- Simplicity : To simplify collaboration, the security solution must be integrated into the DevOps teams' universe. Thus, the same tools, languages and concepts must be used.
- Visibility : It is necessary to provide visibility to the various users and managers: developers, infrastructure and security. R&S Trusted Application Factory tracks the application from design to production execution, providing indicators on its security throughout its lifecycle.
The R&S Trusted Application Factory application security service is deployed as a container for each application. This container can therefore "evolve" at the same time as the application in Kubernetes or Docker clusters. It can therefore automatically adapt to the application load. It also accompanies the application and can be deployed on-demand as well as on the private or public cloud. All the services are managed from a SaaS administration console, which enables the security of the various applications to be monitored.
The solution is based on the concept of "Context Description" to improve the level of security. Indeed, the data specific to each application and available to the development teams are essential for the configuration of security. The type of persistence used, the programming language, the server operating system and the data formats make it possible to automatically adapt protection policies by invoking the appropriate engines. By taking all these elements into account, increased security and a reduced risk of false positives is achieved.
Rohde & Schwarz Cybersecurity
Rohde & Schwarz Cybersecurity is a leading IT security company that protects the digital assets of companies and public institutions worldwide from cyberattacks.
Rohde & Schwarz
Rohde & Schwarz is a leading supplier of solutions in the fields of test and measurement, broadcast and media, aerospace | defense | security and networks and cybersecurity.
R&S® is a registered trademark of Rohde & Schwarz GmbH & Co KG.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201021005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom